{"ModuleTitle": "Company Description", "CompanyName": "Epizyme, Inc.", "Symbol": "EPZM", "Address": "400 TECHNOLOGY SQUARE 4TH FLOOR, CAMBRIDGE, Massachusetts, 02139, United States of America", "Phone": "617-229-5872", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company that is committed to rewriting treatment for\r\npeople with cancer and other serious diseases through the discovery,\r\ndevelopment, and commercialization of novel epigenetic medicines. By focusing on\r\nthe genetic drivers of disease, our science seeks to match targeted medicines\r\nwith the patients who need them.\r\n\r\n \r\n\r\nIn January 2020, the U.S. Food and Drug Administration, or FDA, granted\r\naccelerated approval of TAZVERIK(TM) (tazemetostat) for the treatment of adult and\r\npediatric patients aged 16 years and older with metastatic or locally advanced\r\nepithelioid sarcoma not eligible for complete resection. This approval was based\r\non overall response rate and duration of response shown in the epithelioid\r\nsarcoma cohort of our Phase 2 trial in patients with INI1-negative tumors. The\r\ncommercial launch is underway, and we have made TAZVERIK available to eligible\r\npatients and their physicians in the United States.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f27%2f0001564590-20-007398.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Jeffery L. Kutok", "title": "Chief Scientific Officer & Executive VP"}, {"name": "Paolo Tombesi", "title": "Chief Financial Officer"}, {"name": "Robert B. Bazemore", "title": "President, Chief Executive Officer & Director"}, {"name": "Shefali Agarwal", "title": "Chief Medical Officer"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}